US equities |
INTC $92.07 ▲+0.00% SNDK $1,330.05 ▲+0.00% MU $934.27 ▲+0.00% NVDA $213.66 ▲+0.00% GOOGL $283.82 ▲+0.00% AMZN $243.79 ▲+0.00% AAPL $348.91 ▲+0.00% SKHY $162.09 ▲+0.00%
FinancialContent

Articles published by Gain Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Present at the 38th Annual ROTH Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Present at Neuroscience 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
News headline image
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
< Previous 1 2 3 Next >